LIVIVO - Search results -

Search results

Result 1 - 10 of total 19

Search options

Article ; Online: Een pasgeborene met vaattekening op de buik.

Bosma, Angela L / Van der Zwaan, Dave

2022 Volume 166

Abstract: We describe the case of a 3-week-old boy showing telangiectasias on the abdominal skin since 2 weeks. His medical (family) history and an abdominal echo showed no abnormalities. The diagnosis Transient Abdominal Telangiectasia of the Newborn was made. ...

Title translation	Abdominal telangiectasias in a newborn.
Abstract	We describe the case of a 3-week-old boy showing telangiectasias on the abdominal skin since 2 weeks. His medical (family) history and an abdominal echo showed no abnormalities. The diagnosis Transient Abdominal Telangiectasia of the Newborn was made.
MeSH term(s)	Male ; Infant, Newborn ; Humans ; Telangiectasis/diagnosis ; Abdomen/diagnostic imaging ; Skin
Language	Dutch
Publishing date	2022-10-05
Publishing country	Netherlands
Document type	Case Reports ; English Abstract ; Journal Article
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Selection Process for a Web-Based Application to Measure Patient-Reported Outcomes Following the Example of the TREAT NL Registry.

de Groot, Rowdy / Bosma, Angela L / Cornet, Ronald / Spuls, Phyllis I

The Journal of investigative dermatology

2020 Volume 141, Issue 6, Page(s) 1592–1595.e1

MeSH term(s)	Dermatitis, Atopic/diagnosis ; Dermatitis, Atopic/therapy ; Humans ; Immunologic Factors/therapeutic use ; Internet/standards ; Internet/statistics & numerical data ; Netherlands ; Patient Reported Outcome Measures ; Phototherapy/methods ; Phototherapy/statistics & numerical data ; Registries/standards ; Registries/statistics & numerical data ; Research Design/standards ; Severity of Illness Index ; Treatment Outcome
Chemical Substances	Immunologic Factors
Language	English
Publishing date	2020-11-09
Publishing country	United States
Document type	Letter
ZDB-ID	80136-7
ISSN	1523-1747 ; 0022-202X
ISSN (online)	1523-1747
ISSN	0022-202X
DOI	10.1016/j.jid.2020.10.017
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.124: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study.

Bosma, Angela L / Gerbens, Louise A A / El Khattabi, Hajar / Loeff, Floris C / Duckworth, Michael / Woolf, Richard T / Rispens, Theo / Smith, Catherine H / Spuls, Phyllis I

The Journal of dermatological treatment

2023 Volume 34, Issue 1, Page(s) 2193663

Abstract: Background: Dupilumab is prescribed in one dosage across adult atopic dermatitis patients. Differences in drug exposure may explain variation in treatment response.: Objective: Investigating the clinical relevance of dupilumab serum concentration in ... ...

Abstract	Background: Dupilumab is prescribed in one dosage across adult atopic dermatitis patients. Differences in drug exposure may explain variation in treatment response. Objective: Investigating the clinical relevance of dupilumab serum concentration in atopic dermatitis in real-world practice. Methods: In two centers (Netherlands, UK), adults treated with dupilumab for atopic dermatitis were evaluated for effectiveness and safety pretreatment and at 2, 12, 24, and 48 weeks; trough serum samples were analyzed for dupilumab concentration at corresponding time points. Results: In 149 patients, median dupilumab levels during follow-up ranged from 57.4 to 72.4 μg/mL. Levels showed high inter-patient and low intra-patient variability. No correlation was found between levels and ΔEASI. At 2 weeks, levels of ≥64.1 μg/mL predict EASI ≤7 at 24 weeks (specificity:100%, sensitivity:60%; Conclusion: At the on-label dosage, the measured range of dupilumab levels does not seem to yield differences in treatment effectiveness. However, disease activity does seem to influence dupilumab levels - higher baseline disease activity results in lower levels at follow-up.
MeSH term(s)	Adult ; Humans ; Dermatitis, Atopic/drug therapy ; Clinical Relevance ; Prospective Studies ; Injections, Subcutaneous ; Severity of Illness Index ; Treatment Outcome ; Double-Blind Method
Chemical Substances	dupilumab (420K487FSG)
Language	English
Publishing date	2023-04-26
Publishing country	England
Document type	Journal Article
ZDB-ID	1036299-x
ISSN	1471-1753 ; 0954-6634
ISSN (online)	1471-1753
ISSN	0954-6634
DOI	10.1080/09546634.2023.2193663
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2627: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Work ability and quality of working life in atopic dermatitis patients treated with dupilumab.

Bosma, Angela L / Ouwerkerk, Wouter / Günal, Merve / Hyseni, Ariënna M / Arents, Bernd W M / Gerbens, Louise A A / Middelkamp-Hup, Maritza A / de Boer, Angela G E M / Spuls, Phyllis I

The Journal of dermatology

2021 Volume 48, Issue 9, Page(s) 1305–1314

Abstract: Atopic dermatitis is associated with work productivity loss. Little is known about how patients perceive their work ability and quality of working life, and how this is affected by treatment. Our primary objective was to investigate work ability and ... ...

Abstract	Atopic dermatitis is associated with work productivity loss. Little is known about how patients perceive their work ability and quality of working life, and how this is affected by treatment. Our primary objective was to investigate work ability and quality of working life at baseline and during treatment in the long term. A registry-embedded prospective observational cohort study was conducted consisting of patients with atopic dermatitis starting dupilumab in routine clinical care. The instruments used were the Work Ability Index (WAI; questions 1, 2, and 3) and the Quality of Working Life Questionnaire (QWLQ). Ninety-three patients were included of whom 72 were (self-)employed (77%). From baseline to 48 weeks, the mean WAI-1 score (general work ability, range 0-10) improved from 6.8 (±2.0) to 7.9 (±1.3), WAI-2 (physical work ability, range 1-5) from 3.7 (±0.9) to 4.3 (±0.7), and WAI-3 (mental/emotional work ability, range 1-5) from 3.4 (±0.9) to 3.9 (±0.8) (p = 0.001, p = 0.005, p < 0.001, respectively). The mean QWLQ total score improved from 74.0 (±9.1) to 77.5 (±9.6) and subscale "Problems due to health situation" improved from 37.4 (±22.3) to 61.5 (±23.1) (range 0-100; p = 0.032, p < 0.001, respectively). In conclusion, patients with moderate-to-severe atopic dermatitis starting dupilumab report decreased work ability and quality of working life, mainly due to health-related problems. Significant improvement of work ability and quality of working life is observed with dupilumab treatment.
MeSH term(s)	Antibodies, Monoclonal, Humanized ; Dermatitis, Atopic/drug therapy ; Humans ; Prospective Studies ; Quality of Life ; Severity of Illness Index ; Treatment Outcome ; Work Capacity Evaluation
Chemical Substances	Antibodies, Monoclonal, Humanized ; dupilumab (420K487FSG)
Language	English
Publishing date	2021-05-19
Publishing country	England
Document type	Journal Article ; Observational Study
ZDB-ID	800103-0
ISSN	1346-8138 ; 0385-2407
ISSN (online)	1346-8138
ISSN	0385-2407
DOI	10.1111/1346-8138.15939
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 1950: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Effectiveness of a skin care programme for the prevention of contact dermatitis in healthcare workers (the Healthy Hands Project): A single-centre, cluster randomized controlled trial.

Soltanipoor, Maryam / Kezic, Sanja / Sluiter, Judith K / de Wit, Fleur / Bosma, Angela L / van Asperen, Ruth / Rustemeyer, Thomas

Contact dermatitis

2019 Volume 80, Issue 6, Page(s) 365–373

Abstract: Background: Healthcare workers (HCWs) are at risk of developing hand dermatitis (HD). Guidelines recommend moisturizers to prevent HD, but in practice their effectiveness has been poorly investigated.: Objectives: To assess whether an intervention ... ...

Abstract	Background: Healthcare workers (HCWs) are at risk of developing hand dermatitis (HD). Guidelines recommend moisturizers to prevent HD, but in practice their effectiveness has been poorly investigated. Objectives: To assess whether an intervention aimed at improving skin care leads to a reduction in HD severity. Methods: In this 1-year randomized controlled trial, 9 wards (285 HCWs) were allocated to an intervention group (IG), and 10 wards (216 HCWs) were allocated to the control group (CG). The intervention included provision of cream dispensers with electronic monitoring of use, regularly communicated to the HCWs. The primary and secondary outcomes were change from baseline in Hand Eczema Severity Index (HECSI) score (ΔHECSI) and change in natural moisturizing factor (NMF) level (ΔNMF). Results: At 12 months, the rates of loss to follow-up were 41% and 39% in the IG and the CG, respectively. The HECSI score was reduced in the IG by -6.2 points (95%CI: -7.7 to -4.7) and in the CG by -4.2 points (95%CI: -6.0 to -2.4). There was no significant difference in ΔHECSI or ΔNMF between the groups. Relative improvement in the HECSI score was significantly higher in the IG than in the CG (56% vs 44%). In a subgroup of HCWs with mild HD, the IG showed a larger HECSI score decrease than the CG (P < 0.001). Conclusion: Although there was no significant effect on the primary outcomes, the intervention showed overall positive effects on the HECSI score.
MeSH term(s)	Dermatitis, Allergic Contact/prevention & control ; Dermatitis, Occupational/prevention & control ; Female ; Hand Dermatoses/prevention & control ; Health Personnel ; Humans ; Male ; Severity of Illness Index ; Skin Cream/administration & dosage
Language	English
Publishing date	2019-03-15
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	193121-0
ISSN	1600-0536 ; 0105-1873
ISSN (online)	1600-0536
ISSN	0105-1873
DOI	10.1111/cod.13214
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1116: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Response to: "Comment on 'Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry'".

Bosma, Angela L / de Wijs, Linde E M / Hof, Michel H / van Nieuwenhuizen, Beau R / Gerbens, Louise A A / Middelkamp-Hup, Maritza A / Hijnen, DirkJan / Spuls, Phyllis I

Journal of the American Academy of Dermatology

2021 Volume 85, Issue 3, Page(s) e173–e174

MeSH term(s)	Antibodies, Monoclonal, Humanized ; Dermatitis, Atopic/drug therapy ; Eczema ; Humans ; Netherlands ; Registries
Chemical Substances	Antibodies, Monoclonal, Humanized ; dupilumab (420K487FSG)
Language	English
Publishing date	2021-03-04
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	603641-7
ISSN	1097-6787 ; 0190-9622
ISSN (online)	1097-6787
ISSN	0190-9622
DOI	10.1016/j.jaad.2021.02.072
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1540: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.

Valk, Anika M / Keijser, Jim B D / van Dam, Koos P J / Stalman, Eileen W / Wieske, Luuk / Steenhuis, Maurice / Kummer, Laura Y L / Spuls, Phyllis I / Bekkenk, Marcel W / Musters, Annelie H / Post, Nicoline F / Bosma, Angela L / Horváth, Barbara / Hijnen, Dirk-Jan / Schreurs, Corine R G / van Kempen, Zoé L E / Killestein, Joep / Volkers, Adriaan G / Tas, Sander W /

Boekel, Laura / Wolbink, Gerrit J / Keijzer, Sofie / Derksen, Ninotska I L / van Deelen, Melanie / van Mierlo, Gerard / Kuijpers, Taco W / Eftimov, Filip / van Ham, S Marieke / Ten Brinke, Anja / Rispens, Theo

Allergy

2024

Abstract: Background: The noninflammatory immunoglobulin G4 (IgG4) is linked to tolerance and is unique to humans. Although poorly understood, prolonged antigenic stimulation and IL-4-signaling along the T helper 2-axis may be instrumental in IgG4 class switching. ...

Abstract	Background: The noninflammatory immunoglobulin G4 (IgG4) is linked to tolerance and is unique to humans. Although poorly understood, prolonged antigenic stimulation and IL-4-signaling along the T helper 2-axis may be instrumental in IgG4 class switching. Recently, repeated SARS-CoV-2 mRNA vaccination has been linked to IgG4 skewing. Although widely used immunosuppressive drugs have been shown to only moderately affect humoral responses to SARS-CoV-2 mRNA vaccination, the effect on IgG4 switching has not been investigated. Methods: Here we study the impact of such immunosuppressive drugs, including the IL-4 receptor-blocking antibody dupilumab, on IgG4 skewing upon repeated SARS-CoV-2 mRNA vaccination. Receptor-binding domain (RBD) specific antibody responses were longitudinally measured in 600 individuals, including patients with immune-mediated inflammatory diseases treated with a TNF inhibitor (TNFi) and/or methotrexate (MTX), dupilumab, and healthy/untreated controls, after repeated mRNA vaccination. Results: We observed a substantial increase in the proportion of RBD-specific IgG4 antibodies (median 21%) in healthy/untreated controls after third vaccination. This IgG4 skewing was profoundly reduced in dupilumab-treated patients (<1%). Unexpectedly, an equally strong suppression of IgG4 skewing was observed in TNFi-treated patients (<1%), whereas MTX caused a modest reduction (7%). RBD-specific total IgG levels were hardly affected by these immunosuppressive drugs. Minimal skewing was observed, when primary vaccination was adenoviral vector-based. Conclusions: Our results imply a critical role for IL-4/IL-13 as well as TNF in vivo IgG4 class switching. These novel findings advance our understanding of IgG4 class switch dynamics, and may benefit humoral tolerance induction strategies, treatment of IgG4 pathologies and mRNA vaccine optimization.
Language	English
Publishing date	2024-03-04
Publishing country	Denmark
Document type	Journal Article
ZDB-ID	391933-x
ISSN	1398-9995 ; 0105-4538
ISSN (online)	1398-9995
ISSN	0105-4538
DOI	10.1111/all.16089
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.150: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 125: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.

Bosma, Angela L / de Wijs, Linde E M / Hof, Michel H / van Nieuwenhuizen, Beau R / Gerbens, Louise A A / Middelkamp-Hup, Maritza A / Hijnen, DirkJan / Spuls, Phyllis I

Journal of the American Academy of Dermatology

2020 Volume 83, Issue 5, Page(s) 1375–1384

Abstract: Background: Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking.: Objective: To investigate patient characteristics, treatment aspects, effectiveness, and safety of up to 84 weeks of dupilumab treatment.: ... ...

Abstract	Background: Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. Objective: To investigate patient characteristics, treatment aspects, effectiveness, and safety of up to 84 weeks of dupilumab treatment. Methods: An observational prospective cohort study was conducted of patients with atopic dermatitis starting dupilumab in routine clinical care. Results: Of the 221 included patients, 103 used systemic therapy at baseline. At 84 weeks, we found a change of -15.2 (SE, 1.7) for the Eczema Area and Severity Index, -16.9 (SE, 1.4) for the Patient-Oriented Eczema Measure, and -17.2 (SE, 1.6) for the Dermatology Life Quality Index. We found a trend for improvement over time for the Investigator Global Assessment and Numerical Rating Scale for pruritus. Severe (n = 79) including serious (n = 11) adverse events were observed in 69 patients. Eye complaints were most frequently reported (n = 46). Twenty-one patients adjusted the regular dosing schedule, and 14 patients discontinued treatment, mainly due to ineffectiveness (n = 7). Limitations: Only adverse events of severe and serious nature were registered for feasibility reasons. Conclusion: Daily practice dupilumab treatment of up to 84 weeks is generally well-tolerated, apart from the reporting of eye complaints. It can be considered a long-term effective treatment for atopic dermatitis in combination with topical and initial concomitant systemic treatment, showing a sustained improvement of signs, symptoms, and quality of life.
MeSH term(s)	Adolescent ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Child ; Child, Preschool ; Dermatitis, Atopic/drug therapy ; Female ; Humans ; Infant ; Male ; Netherlands ; Prospective Studies ; Registries ; Time Factors ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal, Humanized ; dupilumab (420K487FSG)
Language	English
Publishing date	2020-05-30
Publishing country	United States
Document type	Journal Article ; Observational Study
ZDB-ID	603641-7
ISSN	1097-6787 ; 0190-9622
ISSN (online)	1097-6787
ISSN	0190-9622
DOI	10.1016/j.jaad.2020.05.128
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1540: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.

JAAD international

2022 Volume 10, Page(s) 14–24

Abstract: Background: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types.: Objective: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological ... ...

Abstract	Background: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types. Objective: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type. Methods: In an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL (treatregister.nl) and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; astar-register.org) registries, data on morphological phenotypes and treatment outcomes were investigated. Results: A total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, Limitations: Unblinded, non-randomized. Conclusion: Atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.
Language	English
Publishing date	2022-10-10
Publishing country	United States
Document type	Journal Article
ISSN	2666-3287
ISSN (online)	2666-3287
DOI	10.1016/j.jdin.2022.09.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce.

Bosma, Angela L / Musters, Annelie H / Bloem, Manja / Gerbens, Louise A A / Middelkamp-Hup, Maritza A / Haufe, Eva / Schmitt, Jochen / Barbarot, Sebastien / Seneschal, Julien / Staumont-Sallé, Delphine / Johansson, Emma K / Bradley, Maria / von Kobyletzki, Laura B / Vittrup, Ida / Frier Ruge, Iben / Thyssen, Jacob P / Vestergaard, Christian / de Vega, Marina / García-Doval, Ignacio /

Chiricozzi, Andrea / Stingeni, Luca / Calzavara-Pinton, Piergiacomo / Ardern-Jones, Michael R / Reynolds, Nick J / Flohr, Carsten / Spuls, Phyllis I

Journal of the European Academy of Dermatology and Venereology : JEADV

2022 Volume 37, Issue 1, Page(s) 123–136

Abstract: Background: The TREatment of ATopic eczema (TREAT) Registry Taskforce is a collaborative international network of registries collecting data of atopic eczema (AE) patients receiving systemic and phototherapy with the common goal to provide long-term ... ...

Abstract	Background: The TREatment of ATopic eczema (TREAT) Registry Taskforce is a collaborative international network of registries collecting data of atopic eczema (AE) patients receiving systemic and phototherapy with the common goal to provide long-term real-world data on the effectiveness, safety and cost-effectiveness of therapies. A core dataset, consisting of domains and domain items with corresponding measurement instruments, has been developed to harmonize data collection. Objectives: We aimed to give an overview of the status and characteristics of the eight established TREAT registries, and to perform a mapping exercise to examine the degree of overlap and pooling ability between the national registry datasets. This will allow us to determine which research questions can be answered in the future by pooling data. Methods: All eight registries were asked to share their dataset and information on the current status and characteristics. The overlap between the core dataset and each registry dataset was identified (according to the domains, domain items and measurement instruments of the TREAT core dataset). Results and conclusions: A total of 4702 participants have been recruited in the eight registries as of 1st of May 2022. Of the 69 core dataset domain items, data pooling was possible for 69 domain item outcomes in TREAT NL (the Netherlands), 61 items in A-STAR (UK and Ireland), 38 items in TREATgermany (Germany), 36 items in FIRST (France), 33 items in AtopyReg (Italy), 29 items in Biobadatop (Spain), 28 items in SCRATCH (Denmark) and 20 items in SwedAD (Sweden). Pooled analyses across all registries can be performed on multiple important domain items, covering the main aims of analysing data on the (cost-)effectiveness and safety of AE therapies. These results will facilitate future comparative or joint analyses.
MeSH term(s)	Humans ; Dermatitis, Atopic/therapy ; Registries ; Germany ; Phototherapy ; Spain ; Eczema
Language	English
Publishing date	2022-09-10
Publishing country	England
Document type	Journal Article
ZDB-ID	1128828-0
ISSN	1468-3083 ; 0926-9959
ISSN (online)	1468-3083
ISSN	0926-9959
DOI	10.1111/jdv.18566
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3492: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 413: Show issues

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito